ADA Scientific Sessions 2026 Abstract
HM17321, a Novel UCN2 Analog, Improves Weight Loss Quality in Combination with Amylin Analogs in DIO Rats
Experiments in animalsInterventions
Papers by Sang-Hyun Lee
11 results
- ADA Scientific Sessions 2026 Abstract
HM500197, a De Novo–Designed Long-Acting Peptide Myostatin Inhibitor, Improves Skeletal Muscle Mass and Body Composition in Diet-Induced Obese Mice
Experiments in animalsInterventions - ADA Scientific Sessions 2026 Abstract
Cardiorenal Protective Effects of a CRFR2-Selective UCN2 Analog, HM17321, in Spontaneously Hypertensive Rats (SHR)
Experiments in animalsInterventions - ADA Scientific Sessions 2026 Abstract
Body Composition and Functional Outcomes of HM17321, a CRFR2-Selective UCN2 Analog, Alone and in Combination with Myostatin/Activin Inhibition in DIO Mice
Experiments in animalsInterventions
- ADA Scientific Sessions 2026 Abstract
Protective Effects of HM17321, a Novel UCN2 Analog, on Obesity-Associated Musculoskeletal Diseases in Mouse Models
Experiments in animalsInterventions - ADA Scientific Sessions 2026 Abstract
HM17321, a CRFR2 Selective UCN2 Analog, Prevents Muscle Loss and Functional Decline in Sarcopenic Mice
Experiments in miceSarcopenia - ADA Scientific Sessions 2025 Abstract
A Novel UCN2 Analog HM17321 with HM15275 Improves Body Composition in Mouse Model of Obesity
Experiments in animalsInterventions - ADA Scientific Sessions 2025 Abstract
A Novel CRFR2 Selective UCN2 Analog, HM17321, Facilitates Weight Loss and Improves Body Composition across Animal Models of Obesity
Experiments in animalsInterventions - ADA Scientific Sessions 2025 Abstract
A Novel CRFR2-Selective UCN2 Analog, HM17321, Improves Glycemic Control across Multiple Preclinical Models
Experiments in animalsInterventions - ADA Scientific Sessions 2025 Abstract
Robust Antiobesity Effect and Mechanistic Insights of HM15275, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist in Animal Model of Obesity
Experiments in animalsInterventions - ADA Scientific Sessions 2025 Abstract
Metabolic Adaptation of Liver with Treatment of HM15275, a Long-Acting GLP-1/GIP/Glucagon Triple Agonist, Supporting Lean Mass Preservation
Experiments in animalsInterventions